Sales for the first quarter of fiscal year ending March 2027 reached 76.6 billion yen (YoY +80.3%), net income was 5.2 billion yen (YoY +21.7%). Revenue significantly increased driven by strong growth in the medical business.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7774","jir_company_name":"Japan Tissue Engineering Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-07-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/7774-20260730-01.pdf","jir_short_summary":"Sales for the first quarter of fiscal year ending March 2027 reached 76.6 billion yen (YoY +80.3%), net income was 5.2 billion yen (YoY +21.7%). Revenue significantly increased driven by strong growth in the medical business.","jir_summary":"### Performance Overview\nJapan Tissue Engineering Co., Ltd. reported consolidated sales of 76.6 billion yen (YoY +80.3%), operating income of 5.9 billion yen (YoY +66.4%), and net income of 5.2 billion yen (YoY +21.7%) for the first quarter of fiscal year ending March 2027. The strong performance was driven by the robust growth of the medical business segment. The sales increase was mainly due to contributions from regenerative medical products and laboratory site operations, with cost control measures also improving profit margins. Compared to the same period last year, significant growth was achieved, enhancing expectations for future expansion.\n\n### Outlook and Impact on Shareholders\nContinued growth in sales and profits is anticipated through expansion of the medical business and the launch of new products. The company plans to strengthen R&D investments to meet increasing demand in the regenerative medicine field. Shareholders can expect increased dividends and stock price appreciation associated with the profit growth, though ongoing investments to support business expansion may also impact financials. In the medium to long term, the company aims to establish a stable revenue base and enhance shareholder returns.","jir_financial_highlights":"Sales: 76.6 billion yen (YoY +80.3%)\nNet Income: 5.2 billion yen (YoY +21.7%)\nOperating Income: 5.9 billion yen (YoY +66.4%)","jir_category":"","jir_hashtags":"#JapanTissueEngineering, #FinancialResults, #JapaneseStocks","jir_key_figures":"Sales: 76.6 billion yen (YoY +80.3%)\nNet Income: 5.2 billion yen (YoY +21.7%)\nOperating Income: 5.9 billion yen (YoY +66.4%)","jir_meta_title":"\u3010Japan Tissue Engineering\u3011Financial Results for the First Quarter of FY 2027\uff5cSales of 76.6 billion yen (YoY +80.3%)","jir_meta_description":"Japan Tissue Engineering's FY 2027 Q1 financial results show sales of 76.6 billion yen and net income of 5.2 billion yen, marking significant profit growth. Expansion of the medical business and improved profitability are reported.","jir_og_title":"\u3010Japan Tissue Engineering\u3011Financial Results for the First Quarter of FY 2027\uff5cSales of 76.6 billion yen","jir_og_description":"Japan Tissue Engineering's FY 2027 Q1 shows sales of 76.6 billion yen and net income of 5.2 billion yen. The company\u2019s medical business is performing well, with further growth expected.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Sales Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"2026 Q4\\\", \\\"2027 Q1\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Sales\\\", \\\"data\\\": [\\\"unknown\\\", 76.6], \\\"borderColor\\\": \\\"#36A2EB\\\", \\\"fill\\\": false}]} \"}, {\"jir_chart_id\": \"profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"2026 Q4\\\", \\\"2027 Q1\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Net Income\\\", \\\"data\\\": [\\\"unknown\\\", 5.2], \\\"borderColor\\\": \\\"#FF6384\\\", \\\"fill\\\": false}]} \"}, {\"jir_chart_id\": \"operating_margin\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Margin\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"2026 Q4\\\", \\\"2027 Q1\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Operating Margin\\\", \\\"data\\\": [\\\"unknown\\\", \\\"unknown\\\"], \\\"backgroundColor\\\": \\\"#FFCE56\\\"}]} \"}]","ir_related_company":57771,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-89834","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n